Dr Reddy's Rituximab Build-Up And Going Beyond The Pill
Nine years after the launch of its biosimilar rituximab in India, Dr Reddy's Laboratories (DRL) claims a tenfold increase in the number of patients treated with the monoclonal antibody. M V Ramana, DRL's executive vice president and head branded markets (India and emerging countries) tells Scrip about his plans for the product in Russia and elsewhere and the firm's thrust on delivering care beyond the pill.
You may also be interested in...
The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.
Dr. Reddy’s Laboratories (DRL) has reported a slump in profits for the first quarter, dented by a decline in volume growth and pricing pressure in the US as well as a loss of business in Venezuela. While the firm's long term story appears intact, resolution of compliance issues at its Indian sites and product flows in the US and other markets (DRL expects to participate in a Russian tender for rituximab) could lift investor sentiment significantly.
The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.